Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.76
+0.04001.47%
Post-market: 2.790.0300+1.09%19:30 EDT
Volume:2.62M
Turnover:7.23M
Market Cap:314.64M
PE:-2.08
High:2.82
Open:2.77
Low:2.69
Close:2.72
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:70.82M
Volume Ratio:1.63
T/O Rate:3.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.3971
ROE:-39.57%
ROA:-22.28%
PB:0.97
PE(LYR):-1.98

Loading ...

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Tenaya Therapeutics (TNYA)

TIPRANKS
·
Jul 06

Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline

TIPRANKS
·
Jul 02

Perspective Therapeutics management to meet virtually with BTIG

TIPRANKS
·
Jun 27

Perspective Therapeutics doses first meningioma patient in Phase 1/2a trial of [212Pb]VMT-α-NET

Reuters
·
Jun 03

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed With [212PB]Vmt-Α-Net in the Meningioma Cohort of a Phase 1/2a Study

THOMSON REUTERS
·
Jun 03

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

GlobeNewswire
·
Jun 03

Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer

TIPRANKS
·
Jun 01

H.C. Wainwright Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Jun 01

Perspective Therapeutics shareholders elect six directors at annual meeting

Reuters
·
May 28

Perspective Therapeutics reports 29% response rate in [212Pb]VMT01 melanoma cohort 3.0 mCi trial

Reuters
·
May 22

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

GlobeNewswire
·
May 22

Perspective Therapeutics doses first patients in two Phase 1/2a studies

TIPRANKS
·
May 18

Perspective Therapeutics doses first patient in new VMT-α-NET Phase 1/2a cohort

Reuters
·
May 18

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

THOMSON REUTERS
·
May 18

LifeSci Capital Remains a Buy on Perspective Therapeutics (CATX)

TIPRANKS
·
May 16

Perspective Therapeutics price target lowered to $6 from $7 at BofA

TIPRANKS
·
May 13

Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX)

TIPRANKS
·
May 12

Piper Sandler Remains a Buy on Perspective Therapeutics (CATX)

TIPRANKS
·
May 12

BTIG Remains a Buy on Perspective Therapeutics (CATX)

TIPRANKS
·
May 12

RBC Capital Sticks to Its Buy Rating for Perspective Therapeutics (CATX)

TIPRANKS
·
May 12